Immunome (NASDAQ:IMNM) Receives Buy Rating from HC Wainwright

Immunome (NASDAQ:IMNM)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $40.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 76.29% from the stock’s previous close.

IMNM has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Truist Financial raised Immunome to a “strong-buy” rating in a report on Monday, May 4th. Craig Hallum lifted their price objective on Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Stephens cut their price objective on Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $31.00 price objective on shares of Immunome in a report on Thursday, January 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $33.45.

Immunome Trading Down 1.3%

Immunome stock opened at $22.69 on Wednesday. The firm has a market cap of $2.57 billion, a price-to-earnings ratio of -9.38 and a beta of 2.11. The stock has a fifty day simple moving average of $21.98 and a two-hundred day simple moving average of $21.10. Immunome has a 12 month low of $7.42 and a 12 month high of $27.65.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. On average, equities research analysts forecast that Immunome will post -2.5 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Jack Higgins sold 9,438 shares of Immunome stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $21.64, for a total value of $204,238.32. Following the completion of the sale, the insider owned 22,000 shares of the company’s stock, valued at $476,080. The trade was a 30.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Max Rosett sold 65,000 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total value of $1,424,800.00. Following the sale, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at $1,184,491.04. This represents a 54.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 139,438 shares of company stock valued at $2,964,664 over the last 90 days. Company insiders own 7.21% of the company’s stock.

Institutional Trading of Immunome

Hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC grew its holdings in Immunome by 3,513.0% during the third quarter. Nisa Investment Advisors LLC now owns 80,426 shares of the company’s stock valued at $942,000 after purchasing an additional 78,200 shares during the period. Nan Fung Trinity HK Ltd. grew its holdings in Immunome by 7.9% during the third quarter. Nan Fung Trinity HK Ltd. now owns 592,103 shares of the company’s stock valued at $6,934,000 after purchasing an additional 43,253 shares during the period. NEOS Investment Management LLC grew its holdings in Immunome by 40.5% during the third quarter. NEOS Investment Management LLC now owns 162,186 shares of the company’s stock valued at $1,899,000 after purchasing an additional 46,755 shares during the period. Pivotal bioVenture Partners Investment Advisor LLC bought a new position in shares of Immunome in the third quarter worth about $5,884,000. Finally, Principal Financial Group Inc. boosted its stake in shares of Immunome by 222.3% in the third quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company’s stock worth $12,939,000 after acquiring an additional 762,147 shares during the period. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.